Shilpa Medicare Peer Comparison

NSE: SHILPAMED | BSE: 530549

₹1,037.70

₹4.55 (0.44%)

As on 23-Sep-2026IST

Market cap

₹20,284 Cr

Revenue (TTM)

₹1,682 Cr

P/E Ratio

68.2

P/B Ratio

7.6

Div. Yield

0.1 %

Edit

	Shilpa Medicare	Caplin Point Lab	Eris Lifesciences	Pfizer	Astrazeneca Pharma
Market cap (₹ Cr)	20,284	21,217	17,618	18,377	16,773
Revenue (₹ Cr)	1,682	2,287	3,230	2,570	2,432
Net Profit (₹ Cr)	273.51	678.07	666.92	735.15	169.62
Net Margin (%)	16.19	28.10	20.60	26.88	6.90
RoE (%)	11.15	19.73	18.75	19.16	20.76
Price to Earnings	68.22	31.89	27.36	25.00	98.89
Price-To-Book	7.55	5.78	4.37	4.17	18.55

Income Statement (₹ Cr)

	Shilpa Medicare	Caplin Point Lab	Eris Lifesciences	Pfizer	Astrazeneca Pharma
Operating Revenue	1,682.47	2,287.33	3,229.67	2,569.77	2,432.06
Total Income	1,689.83	2,413.29	3,237.12	2,735.39	2,458.54
Total Expenditure	1,203.91	1,490.75	2,090.06	1,628.14	2,202.20
EBITDA	478.55	796.58	1,139.61	941.63	229.86
Depreciation	126.01	78.10	281.06	57.58	17.24
EBIT	352.55	718.48	858.55	884.05	212.62
Interest	52.11	0.88	190.64	7.69	5.72
Other Income	7.37	125.96	7.45	165.62	26.48
Exceptional Items	12.16	0.00	-17.24	-49.16	-5.13
Profit before Tax	319.96	843.56	658.12	992.82	228.25
Provision for Tax	46.45	165.49	-8.80	257.67	58.63
Profit after Tax	273.51	678.07	666.92	735.15	169.62

	Shilpa Medicare	Caplin Point Lab	Eris Lifesciences	Pfizer	Astrazeneca Pharma
Shareholder's Funds	2,591.20	3,586.42	3,902.67	4,202.90	872.79
Minority Interest	0.00	-12.71	-21.81	0.00	0.00
Non-Current Liabilities	266.35	28.74	1,392.75	91.50	134.50
Current Liabilities	848.06	385.94	2,077.10	627.48	981.81
Total Liabilities	3,705.61	4,037.51	7,246.72	4,921.88	2,414.58

	Shilpa Medicare	Caplin Point Lab	Eris Lifesciences	Pfizer	Astrazeneca Pharma
Non-Current Assets	2,525.44	1,291.22	5,617.77	770.28	42.47
Current Assets	1,109.77	2,585.66	1,539.85	3,803.22	1,739.93
Total Assets	3,705.61	4,037.51	7,246.72	4,921.88	2,414.58
Total Debt*	657.97	0.57	2,309.68	2.50	0.00
Net Current Assets	261.71	2,199.72	-537.25	3,175.74	758.12
Contingent Liabilities	160.01	17.53	51.57	370.49	121.23

	Shilpa Medicare	Caplin Point Lab	Eris Lifesciences	Pfizer	Astrazeneca Pharma
Cash From Operating Activities	342.18	523.24	537.99	967.57	-15.14
Cash Flow from Investing Activities	-325.92	-582.30	-369.46	-561.67	18.69
Cash from Financing Activities	13.62	-46.46	-313.53	-798.31	-91.97
Net Cash Inflow / Outflow	29.88	-105.52	-145.00	-392.41	-88.42

	Shilpa Medicare	Caplin Point Lab	Eris Lifesciences	Pfizer	Astrazeneca Pharma
ROCE (%)	11.43	24.97	14.47	23.39	31.24
ROE (%)	11.15	19.73	18.75	19.16	20.76
ROA (%)	7.80	18.69	9.26	14.95	9.67
EBIT Margin (%)	20.95	31.41	26.58	34.40	8.74
Net Margin (%)	16.19	28.10	20.60	26.88	6.90
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	Shilpa Medicare	Caplin Point Lab	Eris Lifesciences	Pfizer	Astrazeneca Pharma
Revenue Growth (%)	27.91	15.01	9.59	10.69	31.10
EBIT Growth (%)	58.32	18.45	16.84	24.14	-12.99
Net Profit Growth (%)	149.56	19.61	62.68	-9.09	-7.49
EPS Growth (%)	-3.57	17.73	67.41	14.40	-18.33
Book Value Growth (%)	9.67	26.75	36.71	-0.34	13.51

	Shilpa Medicare	Caplin Point Lab	Eris Lifesciences	Pfizer	Astrazeneca Pharma
Price / Earnings	72.37	31.89	26.67	23.82	96.65
Price / Book Value	7.55	5.78	4.37	4.17	18.55
Dividend Yield (%)	0.06	0.29	0.00	1.87	0.54
EV/EBITDA	43.67	25.37	17.43	16.22	71.02
Market Cap (₹ Cr)	6,819.66	11,439.22	17,980.08	21,592.90	19,398.64

	Shilpa Medicare	Caplin Point Lab	Eris Lifesciences	Pfizer	Astrazeneca Pharma
Debt to Equity	0.07	0.00	0.24	0.00	0.00
Short term debt to equity ratio	0.16	0.00	0.12	0.00	--
Current Ratio	1.31	6.70	0.74	6.06	1.77
Quick Ratio	0.88	5.59	0.53	5.31	0.73
Interest Coverage	7.14	959.59	4.45	130.11	40.90

	Shilpa Medicare	Caplin Point Lab	Eris Lifesciences	Pfizer	Astrazeneca Pharma
Debtors to sales (%)	30.84	36.10	21.07	7.07	8.79
Asset Turnover	0.48	0.63	0.45	0.52	1.39
Receivable days	113.81	121.68	63.88	26.06	31.88
Inventory Days	84.76	63.83	43.27	65.95	126.03
Payable days	101.94	108.28	151.85	81.01	163.79
Cash Conversion Cycle	96.62	77.23	-44.70	11.00	-5.88

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.